Lilly to Provide Detailed Review of Elanco Animal Health and Alzheimer's R&D Strategy at Investment Community Meeting

Nov 20, 2015, 10:00 ET from Eli Lilly and Company

INDIANAPOLIS, Nov. 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media.

The meeting will take place Tuesday, December 8, 2015, from 9:00 a.m. (EST) until approximately 4:00 p.m., at the Four Seasons Hotel in Boston. 

In the meeting, company leaders will provide an overview of Elanco, Lilly's animal health business, and present a comprehensive survey of the company's Alzheimer's disease research program. There will be Q&A opportunities throughout the meeting.

"We look forward to providing details on two key areas of focus for our company, animal health and Alzheimer's disease," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "We will review Elanco's strategy and its growth prospects. Since the acquisition of Novartis Animal Health in January, Elanco has emerged as a top-tier animal health company. In addition, investors can expect to learn more about Lilly's broad research efforts aimed at improving the diagnosis and treatment of Alzheimer's disease."

A live webcast of the Lilly investment community meeting, along with presentation slides, will be available through a link on the investor section of Lilly's website at The webcast will be available for replay over the next 12 months.

Media interested in attending in person should contact Lauren Zierke at (317) 277-6524. Investors interested in attending should contact Edward Villacorta at (317) 433-1805.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and  (C-LLY)

Refer to:     Lauren Zierke;; 317-277-6524 (Media)
                   Phil Johnson;; 317-655-6874 (Investors)

Logo -

SOURCE Eli Lilly and Company